rTMS Treatment of Primary Progressive Aphasia

Last updated: January 10, 2024
Sponsor: Peking Union Medical College Hospital
Overall Status: Completed

Phase

N/A

Condition

Speech Disorders

Frontotemporal Dementia

Memory Loss

Treatment

Magstim rTMS

Clinical Study ID

NCT04431401
PPA-rTMS
  • Ages 35-75
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Primary Progressive Aphasia (PPA) is a neurodegenerative disease in which language function is gradually and progressively impaired. Patients will eventually be disabled in communication and have cognition deficits, which put a heavy burden not only on their families but also on the whole society. However, no effective treatment for PPA has been explored so far. The current clinical randomized trial is to study the safety and efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of PPA. Also, multi-modality of neuroimaging techniques, such as functional MRI and PET will be used to investigate brain network changing in this procedure.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of PPA

Exclusion

Exclusion Criteria:

  • Scored below 15 on the mini-mental state exam (MMSE)
  • history of seizures or unexplained loss of consciousness
  • pregnancy
  • surgical breach of the skull
  • MRI contraindication

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Magstim rTMS
Phase:
Study Start date:
July 01, 2020
Estimated Completion Date:
August 31, 2022

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing 100730
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.